Bicara Therapeutics (BCAX) details Q2 2025 financial results in press release

Rhea-AI Filing Summary

Bicara Therapeutics Inc. filed a current report to note that it has released its financial results and business highlights for the quarter ended June 30, 2025. On August 12, 2025, the company issued a press release describing its quarterly performance and key developments.

The press release is attached as Exhibit 99.1 and is incorporated by reference for informational purposes, but is designated as furnished rather than filed under the Exchange Act. The filing also includes an Inline XBRL cover page data file as Exhibit 104.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

FALSE000202365800020236582025-08-122025-08-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): August 12, 2025

___________________________________

Bicara Therapeutics Inc.

(Exact name of registrant as specified in its charter)

___________________________________

Delaware (State or other jurisdiction of incorporation or organization)			001-42271 (Commission File Number)			85-2903745 (I.R.S. Employer Identification Number)
116 Huntington Avenue, Suite 703 Boston, MA 02116
(Address of principal executive offices and zip code)
(617) 468-4219
(Registrant's telephone number, including area code)

___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class			Trading Symbol			Name of each exchange on which registered
Common Stock, $0.0001 par value			BCAX			The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.

Emerging growth company    ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 - Results of Operations and Financial Condition.

On August 12, 2025, Bicara Therapeutics Inc. (the “Company”) issued a press release announcing its financial results and business highlights for the quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 - Financial Statements and Exhibits

(d) The following exhibits are being filed herewith:

Exhibit No.						Description
99.1						Press Release of Bicara Therapeutics Inc. dated August 12, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 12th day of August, 2025.

Bicara Therapeutics Inc.
By:			/s/ Claire Mazumdar
Name:			Claire Mazumdar
Title:			Chief Executive Officer

FAQ

What did Bicara Therapeutics Inc. (BCAX) disclose in this 8-K?

Bicara Therapeutics Inc. disclosed that it issued a press release on August 12, 2025 announcing its financial results and business highlights for the quarter ended June 30, 2025.

Which period’s results does Bicara Therapeutics Inc. (BCAX) cover in this update?

The update covers Bicara Therapeutics Inc.’s financial results and business highlights for the quarter ended June 30, 2025.

How are the Bicara Therapeutics Inc. (BCAX) results provided to investors?

The results are provided through a press release that is attached as Exhibit 99.1 to the report and incorporated by reference for informational purposes.

Are the Bicara Therapeutics Inc. (BCAX) results considered filed with the SEC?

The company states that the information under Item 2.02 and in Exhibit 99.1 is furnished and not deemed filed for purposes of Section 18 of the Exchange Act.

Which exhibits are included with this Bicara Therapeutics Inc. (BCAX) 8-K?

The report includes Exhibit 99.1, the press release dated August 12, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Who signed this Bicara Therapeutics Inc. (BCAX) 8-K report?

The report was signed on behalf of Bicara Therapeutics Inc. by Claire Mazumdar, Chief Executive Officer.